about
Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancerBone-Targeted Imaging and Radionuclide Therapy in Prostate CancerTargeted α-particle therapy of bone metastases in prostate cancerA unique alpha dosimetry technique using Gafchromic EBT3(®) film and feasibility study for an activity calibrator for alpha-emitting radiopharmaceuticals.Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.Prostate cancer: radium-223: a new treatment option for bone-metastatic CRPC.
P2860
Q26861575-4E2CEA9C-0371-4705-A414-58C43B91CB1CQ27024795-2A53A8A8-5CBD-4FDA-9575-2967741C8B95Q37390666-5261D56A-C811-41BF-A601-E720B357111AQ37417656-193403CC-DF99-4D6F-92E8-9EC0226FC5A4Q40462195-27318EED-F744-4492-A602-E1ADCCFE2B3EQ44355532-A11737AC-BB1E-4702-B19E-F21EF7D21131Q44428782-A9BD77D7-D1F6-4C96-8B58-9C08D62EAC5C
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Radium-223 for the treatment of prostate cancer.
@en
type
label
Radium-223 for the treatment of prostate cancer.
@en
prefLabel
Radium-223 for the treatment of prostate cancer.
@en
P2860
P1476
Radium-223 for the treatment of prostate cancer.
@en
P2093
Christopher Parker
Shaista Hafeez
P2860
P304
P356
10.1517/13543784.2013.761974
P407
P577
2013-01-15T00:00:00Z